Immune Response to SARS-CoV-2 Vaccination in Cancer Patients: A Prospective Study
Authors:
Open Access
- 1 April 2023
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 15 (4)
Abstract
Introduction Cancer patients on active treatment are at increased risk of developing coronavirus disease 2019 (COVID-19), making effective immunization of the utmost importance. However, the effectiveness of vaccination in this population is still unclear. This study aims to evaluate the response against COVID-19 in a cohort of patients with active cancer under immunosuppressive therapy. Methods This was a prospective, cross-sectional, single-center study that included patients with cancer under immunosuppressive therapy vaccinated against COVID-19 between April and September 2021. Exclusion criteria were: previous known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, single-dose vaccine or incomplete vaccination scheme. Immunoglobulin G (IgG) anti-SARS-CoV-2 antibody levels were assessed using 35.2 binding antibody units (BAU)/mL as the positive cut-off. Assessments were performed 14-31 days after the first and second dose and three months after the second dose. Results A total of 103 patients were included. The median age was 60 years. Most patients were being treated for gastrointestinal cancer (n=38, 36.9%), breast cancer (n=33, 32%) or head and neck cancer (n=18, 17.5%). At evaluation, 72 patients (69.9%) were being treated with palliative intent. The majority were being treated with chemotherapy (CT) alone (57.3%). At the first assessment, levels of circulating SARS-CoV-2 IgG consistent with seroconversion were present in 49 patients (47.6%). At the time of the second assessment, 91% (n=100) achieved seroconversion. Three months after the second dose, 83% (n=70) maintained levels of circulating SARS-CoV-2 IgG consistent with seroconversion. In this study, no SARS-CoV-2 infection was reported in the study population. Conclusions Our findings suggest that this group of patients had a satisfactory COVID-19 immunization response. Although promising, this study should be replicated on a wider scale in order to validate these findings.Keywords
This publication has 24 references indexed in Scilit:
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- SARS-CoV-2 vaccines for cancer patients: a call to actionEuropean Journal of Cancer, 2021
- Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future InfectionJAMA Internal Medicine, 2021
- SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)European Journal of Cancer, 2021
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingNew England Journal of Medicine, 2021
- Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we needSignal Transduction and Targeted Therapy, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studiesEuropean Journal of Cancer, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020